List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Oral Mucositis - Overview
Oral Mucositis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Oral Mucositis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Oral Mucositis - Companies Involved in Therapeutics Development
Allander Biotechnologies LLC
Clevexel Pharma SA
Connext Co Ltd
Destiny Pharma Plc
GlycoMira Therapeutics Inc
Lakewood-Amedex Inc
Matrix Biomed Inc
MitoImmune Therapeutics Inc
Moberg Pharma AB
Spectrum Pharmaceuticals Inc
VasoDynamics Ltd
Oral Mucositis - Drug Profiles
bupivacaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
CVXL-0095 - Drug Profile
Product Description
Mechanism Of Action
epinephrine - Drug Profile
Product Description
Mechanism Of Action
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KMRC-011 - Drug Profile
Product Description
Mechanism Of Action
levoleucovorin calcium - Drug Profile
Product Description
Mechanism Of Action
History of Events
MIT-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Nu-3 - Drug Profile
Product Description
Mechanism Of Action
pralatrexate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombinant Protein to Agonize FGFRs for Oral Mucositis - Drug Profile
Product Description
Mechanism Of Action
Recombinant Protein to Antagonize TGF beta for Immunology, Dermatology, Gastrointestinal and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Bacterial Infections and Oral Mucositis - Drug Profile
Product Description
Mechanism Of Action
suramin - Drug Profile
Product Description
Mechanism Of Action
Tempol - Drug Profile
Product Description
Mechanism Of Action
History of Events
Oral Mucositis - Dormant Projects
Oral Mucositis - Discontinued Products
Oral Mucositis - Product Development Milestones
Featured News & Press Releases
Apr 06, 2021: MitoImmune received FDA clearance of IND application for MIT-001, a novel anti-inflammatory/anti-necrotic therapy for oral mucositis in CCRT patients with head and neck cancer
Jan 07, 2021: OncoZenge announces issue of European patent related to BupiZenge
Nov 06, 2020: Moberg Pharma intends to distribute and separately list BupiZenge (BUPI)
Dec 03, 2018: Spectrum Pharmaceuticals announces positive results from phase 2 trial evaluating use of oral Leucovorin to potentially Mitigate Mucositis in patients treated with FOLOTYN (pralatrexate)
May 02, 2018: Moberg Pharma: U.S. Patent Granted For BUPI
Sep 01, 2017: Canadian patent Granted for BUPI
Sep 01, 2017: Phase 2-results for BUPI Published
Oct 19, 2016: European Patent granted for BUPI
Jan 11, 2016: Moberg Pharma Announces Positive Phase II Data for BUPI
Jun 24, 2015: Moberg Pharma To Receive Eurostars Grant Of Eur 0.9 Million
Oct 28, 2014: First Patient Included in Phase ll Study of BUPI, a Novel Topical Formulation for Treatment of Oral Pain
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Oral Mucositis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Oral Mucositis - Pipeline by Allander Biotechnologies LLC, 2022
Oral Mucositis - Pipeline by Clevexel Pharma SA, 2022
Oral Mucositis - Pipeline by Connext Co Ltd, 2022
Oral Mucositis - Pipeline by Destiny Pharma Plc, 2022
Oral Mucositis - Pipeline by GlycoMira Therapeutics Inc, 2022
Oral Mucositis - Pipeline by Lakewood-Amedex Inc, 2022
Oral Mucositis - Pipeline by Matrix Biomed Inc, 2022
Oral Mucositis - Pipeline by MitoImmune Therapeutics Inc, 2022
Oral Mucositis - Pipeline by Moberg Pharma AB, 2022
Oral Mucositis - Pipeline by Spectrum Pharmaceuticals Inc, 2022
Oral Mucositis - Pipeline by VasoDynamics Ltd, 2022
Oral Mucositis - Dormant Projects, 2022
Oral Mucositis - Discontinued Products, 2022

List of Figures
Number of Products under Development for Oral Mucositis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Companies Mentioned
• Allander Biotechnologies LLC
• Clevexel Pharma SA
• Connext Co Ltd
• Destiny Pharma Plc
• GlycoMira Therapeutics Inc
• Lakewood-Amedex Inc
• Matrix Biomed Inc
• MitoImmune Therapeutics Inc
• Moberg Pharma AB
• Spectrum Pharmaceuticals Inc
• VasoDynamics Ltd